NA17.A2 peptide vaccine

{
  "id": "MLC-T-ONC-015399",
  "term": "NA17.A2 peptide vaccine",
  "field": "Oncology and biomedicine",
  "definition": "A peptide cancer vaccine comprised of human leukocyte antigen HLA-A2-restricted peptide derived from a metastatic melanoma cell line of patient NA17, with potential immunomodulating and antineoplastic activity. NA17.A2 peptide vaccine may stimulate a cytotoxic T lymphocyte (CTL) response against tumors that express this antigen, which may result in a reduction in tumor size. This NA17 specific antigen, encoded by an intron sequence of N-acetylglucosaminyltransferase V (GnT-V) gene, is expressed in about 50% of melanomas.",
  "synonyms": [
    "NA17.A2"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/na17-a2-peptide-vaccine/"
}